Abstract:A80 RH1 (2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone) is a novel antitumor diaziridinyl benzoquinone derivative designed to be bioactivated by the two-electron reductase, NAD(P)H:quinone oxidoreductase (NQO1), which has been shown to be expressed at high levels in many solid tumors including lung, colon, pancreas and breast. RH1 is a very efficient substrate for NQO1 and reduction by NQO1 to the hydroquinone results in activation of the aziridine rings and subsequent DNA alkylation and interstrand cross linking. The purpose of this study was to investigate whether other reducing enzymes such as cytochrome b5 reductase (b5R), cytochrome P450 reductase (P450R), NRH:quinone oxidoreductase 2 (NQO2), and xanthine oxidoreductase (XDH/XO) were also involved in the bioactivation and cytotoxicity of RH1 in human breast cancer cells. For these studies, we stably transfected the human breast cancer cell line MDA468 with either human NQO1, b5R or P450R and established a series of stable MDA468 cell lines over-expressing various levels of NQO1, b5R and P450R. RH1-induced growth inhibition (MTT analysis) and genotoxicity (interstrand DNA crosslinking/COMET analysis) was then compared in both parental MDA468 cells and transfected clones. RH1 toxicity was significantly higher in NQO1 transfected MDA468 cells (NQ16) compared to parental MDA468 cells, confirming the principal role of NQO1 in the bioactivation and cytotoxicity of RH1. In these studies RH1 cytotoxicity did not correlate with either b5R or P450R activity levels in a series of b5R or P450R over-expressing MDA468 cell clones. An increase in RH1-induced DNA cross-linking was only observed at very high RH1 doses in clones with the highest levels of b5R or P450R activity, suggesting that the role of b5R and P450R in the bioactivation and cytotoxicity of RH1 will be minor in cancer cells with normal levels of b5R and P450R activity. Enzymatic assays and HPLC studies showed that RH1 was an in vitro substrate for both xanthine oxidase and NQO2. However, pretreatment of MDA468 cells with the XO/XDH inhibitor allopurinol failed to protect MDA468 cells from RH1 toxicity, suggesting that XO/XDH is not playing an important role in these cells. Pretreatment of MDA468 cells with NRH, a cofactor for NQO2, significantly increased the toxicity of RH1, suggesting that NQO2 is capable of bioactivating RH1 in cells in the presence of cofactor. Whether NQO2 is involved in RH1 bioactivation in vivo still remains unclear and will depend on the availability of co-factor in vivo. While these studies suggest that NQO1 is the principal enzyme responsible for RH1 bioactivation and that b5R, P450R and XDH/XO are unlikely to play major roles, they do not rule out a role for additional pathways, including NQO2, in RH1 cytotoxicity.

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

Metabolism of chlorambucil by rat liver microsomal glutathione S-transferase.

Metabolism of melphalan by rat liver microsomal glutathione S-transferase.

Determination of the Potency and Subunit-Selectivity of Ribonucleotide Reductase Inhibitors with a Recombinant-Holoenzyme-based in Vitro Assay.

Dissecting The Role Of Multiple Reductases In Bioactivation And Cytotoxicity Of The Antitumor Agent 2,5-Diaziridinyl-3-(Hydroxymethyl)-6-Methyl-1,4-Benzoquinone (Rh1)

Activation of Mitomycin C by NADPH : Cytochrome P-450 ReducÃ-ase 1

Activation Of Mitomycin-C By Nadph-Cytochrome-P-450 Reductase

Synthesis And Biological Evaluation Of 3-Aryl-Quinoxaline-2-Carbonitrile 1,4-Di-N-Oxide Derivatives As Hypoxic Selective Anti-Tumor Agents

Synthesis and Biological Evaluation of 3-Aryl-quinoxaline-2-carbonitrile 1,4-Di-<em>N</em>-oxide Derivatives as Hypoxic Selective Anti-tumor Agents

In Vitro Study of the Effect of Cyclosporine A, Tetrandrine and Their Combination on the Reversion of Multidrug Resistance in Leukemia Cell Line.

Metabolic-induced cytotoxicity of diosbulbin B in CYP3A4-expressing cells

Correlation of Pharmacokinetic Features and Tissue Distribution with Toxicity of Q39, a Hypoxic Cell Cytotoxic Agent.

Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions.

In Vitro Characterization of the Bacteria-derived Hypoxia-selective Cytotoxin BE-43547

CYP3A5 Mediates Bioactivation and Cytotoxicity of Tetrandrine

Dissecting the role of multiple reductases in activation and cytotoxicity of RH1

Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N

E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance